Adaptimmune Therapeutics (ADAP)
(Delayed Data from NSDQ)
$0.87 USD
-0.01 (-0.84%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $0.87 0.00 (-0.18%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for Adaptimmune Therapeutics PLC falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 147 | 205 | 370 | 368 | 90 |
Receivables | 1 | 7 | 1 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 60 | 43 | 45 | 30 | 31 |
Total Current Assets | 208 | 255 | 415 | 398 | 120 |
Net Property & Equipment | 51 | 54 | 30 | 28 | 31 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 3 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 1 | 2 | 2 |
Deposits & Other Assets | 3 | 2 | 2 | 5 | 5 |
Total Assets | 283 | 329 | 470 | 451 | 182 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 8 | 5 | 8 | 6 | 6 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 30 | 31 | 30 | 27 | 23 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 29 | 26 | 22 | 3 | 2 |
Total Current Liabilities | 73 | 65 | 63 | 39 | 34 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 149 | 161 | 177 | 49 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1 | 1 | 1 | 1 | 1 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 243 | 247 | 264 | 110 | 58 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 2 | 1 | 1 | 1 | 1 |
Capital Surplus | 1,065 | 991 | 960 | 936 | 586 |
Retained Earnings | -1,023 | -909 | -744 | -586 | -456 |
Other Equity | -4 | -1 | -11 | -10 | -7 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 40 | 82 | 206 | 341 | 124 |
Total Liabilities & Shareholder's Equity | 283 | 329 | 470 | 451 | 182 |
Total Common Equity | 40 | 82 | 206 | 341 | 124 |
Shares Outstanding | 227.10 | 164.50 | 156.20 | 154.70 | 105.10 |
Book Value Per Share | 0.17 | 0.50 | 1.32 | 2.21 | 1.18 |
Fiscal Year End for Adaptimmune Therapeutics PLC falls in the month of December.
All items in Millions except Per Share data.
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 215 | 144 | 147 | 162 |
Receivables | NA | 2 | 8 | 1 | 1 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 37 | 35 | 60 | 57 |
Total Current Assets | NA | 254 | 187 | 208 | 219 |
Net Property & Equipment | NA | 46 | 48 | 51 | 53 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 1 | 1 | 0 | 0 |
Deposits & Other Assets | NA | 3 | 3 | 3 | 3 |
Total Assets | NA | 322 | 258 | 283 | 297 |
Liabilities & Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 8 | 7 | 8 | 14 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 31 | 23 | 30 | 27 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 38 | 32 | 29 | 29 |
Total Current Liabilities | NA | 82 | 66 | 73 | 75 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 100 | 147 | 149 | 111 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 25 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 1 | 1 | 1 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 225 | 234 | 243 | 209 |
Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 2 | 2 | 2 | 2 |
Capital Surplus | NA | 1,100 | 1,097 | 1,065 | 1,061 |
Retained Earnings | NA | -1,002 | -1,072 | -1,023 | -975 |
Other Equity | NA | -3 | -3 | -4 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 96 | 24 | 40 | 88 |
Total Liabilities & Shareholder's Equity | NA | 322 | 258 | 283 | 297 |
Total Common Equity | 0 | 96 | 24 | 40 | 88 |
Shares Outstanding | 255.70 | 246.80 | 246.80 | 227.10 | 165.70 |
Book Value Per Share | 0.00 | 0.39 | 0.10 | 0.17 | 0.53 |